Evidence map›Paper›PMID 33626210›Full record

ArticleInternational journal of clinical practice2021

Evaluation of epidemiology, clinical features, prognosis, diagnosis and treatment outcomes of patients with COVID-19 in West Azerbaijan Province.

Naser Gharebaghi, Saman Farshid, Behdad Boroofeh, Rahim Nejadrahim, Jalil Mousavi, Sina Dindarian, Sedra Mohammadi

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Naser GharebaghiDepartment of Infectious Diseases and Dermatology, Urmia University of Medical Sciences, Urmia, Iran.ORCID https://orcid.org/0000-0002-7547-0096
Saman FarshidDepartment of Urology and Nephrology, Urmia University of Medical Sciences, Urmia, Iran.ORCID https://orcid.org/0000-0001-8844-8704
Behdad BoroofehDepartment of Pulmonology, Urmia University of Medical Sciences, Urmia, Iran.ORCID https://orcid.org/0000-0001-7581-5181
Rahim NejadrahimDepartment of Infectious Diseases and Dermatology, Urmia University of Medical Sciences, Urmia, Iran.ORCID https://orcid.org/0000-0003-1676-9722
Jalil MousaviDepartment of Infectious Diseases and Dermatology, Urmia University of Medical Sciences, Urmia, Iran.ORCID https://orcid.org/0000-0002-8385-2086
Sina DindarianStudent Research Committee, Urmia University of Medical Sciences, Urmia, Iran.ORCID https://orcid.org/0000-0001-9702-1665
Sedra MohammadiStudent Research Committee, Urmia University of Medical Sciences, Urmia, Iran.ORCID https://orcid.org/0000-0002-9873-2597
Urmia University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID-19 is considered a widespread concern in global public health. Diagnoses of COVID-19 in some cases are necessary because of severe prognosis. In this study, epidemiologies, clinical and demographic characteristics of patients with COVID-19 were studied in Taleghani Hospital, Urmia, Iran.

methodsThis descriptive-analytical cross-sectional study was carried out on 215 patients with COVID-19 during March and April 2020. Approved COVID-19 case was considered as a person with a positive respiratory sample performed by at least one of two RT-PCR methods or genetic sequencing. ANOVA repeated measure, independent t-test and logistic regression were done. A P < .05 was considered significant.

resultsThe mean age of patients was 50.93 ± 17.92 years. Regarding gender, there were 91 females (42.3%) and 124 males (57.7%). The mean hospital stay, the temperature at admission, and onset of symptoms were 4.91 ± 3.68 days, 37.40 ± 0.96°C and 5.88 ± 4.80 days, respectively. Close contact with suspected people was found in 10.2% of patients. Additionally, 44 patients (20.5%) were smokers. Shortness of breath and cough were found in 62.8% and 49.3% of patients. Diabetes mellitus and hypertension were the most common comorbidities of patients. Regarding lung involvement, 33 patients (33%) were normal, most of the patients (n = 71) had 5%-25% involvement in their lung and a minority of patients (n = 13) had a severe condition of 50%-75% lung involvement. The association between smoking and mortality was tested using chi-square showing no significant difference (X

conclusionCOVID-19 involves different organs of the body with different severity. In the meantime, smoking was not a risk factor for the virus or associated with severe manifestations of the disease. Patients with high creatinine and CPK, pulmonary involvement above 25%, and hypoxemia had a higher mortality rate. Increase of Spo2 by 1% can improve the patients by 24%. The results indicated that Kaletra had the most highest effect on improvement following COVID-19.

Indexed as

COVID-19AdultAgedAzerbaijanCross-Sectional StudiesFemaleHumansIranMaleMiddle AgedPrognosisSARS-CoV-2Treatment Outcome

Identifiers

PMID33626210
PMCPMC7995141
OpenAlexW3133331329

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.